This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Baddigam, K. Articles by Tobias, J. D. Search for Related Content PubMed PubMed Citation Articles by Baddigam, K. Articles by Tobias, J. D. Social Bookmarking                         What's this?

Dexmedetomidine in the Treatment of Withdrawal Syndromes in Cardiothoracic Surgery Patients

Department of Anesthesiology, University of Missouri, Columbia, Missouri

Pierantonio Russo, MD

Department of Cardiothoracic Surgery, University of Missouri, Columbia, Missouri

JoAnne Russo, RN

Department of Nursing, University of Missouri, Columbia, Missouri

Joseph D. Tobias, MD

Departments of Anesthesiology, Pediatrics, University of Missouri, Columbia, Missouri

Dexmedetomidine (Precedex, Abbott Laboratories, Abbott Park, IL) is an• 2adrenergic agonist that possesses a high ratio of specificity for the• 2versus the• 1receptor. It is currently approved for the provision of sedation during mechanical ventilation in adults. Given previous experience with clonidine for the treatment of substance withdrawal and the preliminary anecdotal experience with dexmedetomidine, it appears that dexmedetomidine may be a useful agent for treatment of substance withdrawal in the intensive care setting. The authors present their experience with the use of dexmedetomidine to control withdrawal behavior in 3 patients following cardiothoracic surgery. Previous reports regarding the use of dexmedetomidine to treat withdrawal and its potential application in this clinical arena are reviewed.

Key Words: dexmedetomidine • opioid withdrawal • intensive care unit sedation • abstinence syndromes

Journal of Intensive Care Medicine, Vol. 20, No. 2, 118-123 (2005)
DOI: 10.1177/0885066604273481


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. L Honey, R. J Benefield, J. L Miller, and P. N Johnson {alpha}2-Receptor Agonists for Treatment and Prevention of Iatrogenic Opioid Abstinence Syndrome in Critically Ill Patients Ann. Pharmacother., September 1, 2009; 43(9): 1506 - 1511. [Abstract] [Full Text] [PDF]

				J. Darrouj, N. Puri, E. Prince, A. Lomonaco, A. Spevetz, and D. R Gerber Dexmedetomidine Infusion as Adjunctive Therapy to Benzodiazepines for Acute Alcohol Withdrawal Ann. Pharmacother., November 1, 2008; 42(11): 1703 - 1705. [Abstract] [Full Text] [PDF]

				D. V. Menon, Z. Wang, P. J. Fadel, D. Arbique, D. Leonard, J.-L. Li, R. G. Victor, and W. Vongpatanasin Central Sympatholysis as a Novel Countermeasure for Cocaine-Induced Sympathetic Activation and Vasoconstriction in Humans J. Am. Coll. Cardiol., August 14, 2007; 50(7): 626 - 633. [Abstract] [Full Text] [PDF]

				A. T Gerlach and J. F Dasta Dexmedetomidine: An Updated Review Ann. Pharmacother., February 1, 2007; 41(2): 245 - 252. [Abstract] [Full Text] [PDF]